We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+39.45%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$1.29B
AUM Growth
+$497M
Cap. Flow
+$278M
Cap. Flow %
21.56%
Top 10 Hldgs %
61.71%
Holding
54
New
8
Increased
22
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$51.1M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$44.7M
3
IMMU
Immunomedics Inc
IMMU
+$42.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$39.4M
5
PCRX icon
Pacira BioSciences
PCRX
+$34M

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$43.2M
2
TSRO
TESARO, Inc.
TSRO
+$25.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$17.1M
4
AERI
Aerie Pharmaceuticals
AERI
+$12.1M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 67.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$54.6B
$9.71M 0.75%
429,600
+214,003
+99% +$4.46M
BCRX icon
27
BioCryst Pharmaceuticals
BCRX
$2.35B
$9.32M 0.72%
1,778,525
-175,000
-9% -$896K
ALIM
28
DELISTED
Alimera Sciences
ALIM
$8.43M 0.65%
416,105
+23,333
+6% +$499K
FOLD
29
CALL
DELISTED
Amicus Therapeutics
FOLD
$8.4M 0.65%
3,000,000
+2,750,000
+1,100% +$36.4M
VCYT icon
30
Veracyte
VCYT
$4.77B
$8.22M 0.64%
936,909
+29,313
+3% +$238K
DBVT
31
DBV Technologies
DBVT
$817M
$8.22M 0.64%
+19,360
New +$8.3M
CASC
32
DELISTED
Cascadian Therapeutics, Inc.
CASC
$7.45M 0.58%
1,821,248
– –
IMMU
33
CALL
DELISTED
Immunomedics Inc
IMMU
$6.3M 0.49%
+875,000
New +$8.72M
VIVE
34
DELISTED
VIVEVE MED INC
VIVE
$5.41M 0.42%
1,033
+237
+30% +$1.46M
CLLS
35
Cellectis
CLLS
$287M
$2.23M 0.17%
78,289
-7,400
-9% -$191K
TPST icon
36
Tempest Therapeutics
TPST
$13.8M
$1.59M 0.12%
384
+277
+259% +$1.18M
ARRY
37
CALL
DELISTED
Array Biopharma Inc
ARRY
$1.5M 0.12%
500,000
– –
OTLK icon
38
Outlook Therapeutics
OTLK
$194M
$936K 0.07%
4,272
– –
FENC icon
39
Fennec Pharmaceuticals
FENC
$344M
$731K 0.06%
+66,666
New +$774K
SPY icon
40
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
$469K 0.04%
250,000
– –
ONSIW
41
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$28K ﹤0.01%
233,333
– –
ONSIZ
42
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$12K ﹤0.01%
233,333
– –
ACAD icon
43
Acadia Pharmaceuticals
ACAD
$4.55B
– –
-614,200
Closed -$17.1M
FBIO icon
44
Fortress Biotech
FBIO
$109M
– –
-40,244
Closed -$2.87M
NBIX icon
45
Neurocrine Biosciences
NBIX
$18.7B
– –
-219,500
Closed -$10.1M
PTCT icon
46
PTC Therapeutics
PTCT
$6.26B
– –
-120,000
Closed -$2.2M
SGMO
47
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-800,000
Closed -$7.04M
NVRO
48
DELISTED
NEVRO CORP.
NVRO
– –
-50,000
Closed -$3.72M
SIOX
49
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-10,261
Closed -$1.9M
SRNE
50
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-416,230
Closed -$832K
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Avoro Capital Advisors held 54 positions worth $1.29B, up 63% from $792M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Avoro Capital Advisors deployed $278M of net new capital in Q3 2017, opening 8 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 3,516,100 shares worth $44.6M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 65% a quarter earlier.

On the sell side, the largest reduction was Kite Pharma, Inc., an estimated $43.2M trimmed.

  • Avoro Capital Advisors's largest Q3 2017 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 3,516,100 shares worth $44.6M.
  • Avoro Capital Advisors added most to Clovis Oncology, Inc. in Q3 2017, an estimated $51.1M increase.
  • Avoro Capital Advisors's biggest Q3 2017 reduction was Kite Pharma, Inc., cutting an estimated $43.2M.
  • Avoro Capital Advisors fully exited Acadia Pharmaceuticals in Q3 2017, selling an estimated $17.1M.
  • Avoro Capital Advisors's ten largest holdings make up 62% of its $1.29B portfolio in Q3 2017.
  • Avoro Capital Advisors opened 8 new positions and closed 11 in Q3 2017.
  • Avoro Capital Advisors's portfolio value rose 63% quarter-over-quarter to $1.29B.

Based on Avoro Capital Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.